CNS Pharmaceuticals Inc
Change company Symbol lookup
Select an option...
CNSP CNS Pharmaceuticals Inc
SMTC Semtech Corp
EU enCore Energy Corp
CJET Chijet Motor Co Inc
LAKE Lakeland Industries Inc
JWEL Jowell Global Ltd
SMAR Smartsheet Inc
FOXA Fox Corp
SCVFF Scotch Creek Ventures Inc
VEDU Visionary Education Technology Holdings Group Inc
Go

Health Care : Pharmaceuticals | Small Cap Value
Company profile

CNS Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system (CNS). The Company's lead drug candidate, Berubicin, is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. Berubicin is in development for the treatment of a number of serious brain and CNS oncology indications, including glioblastoma multiforme (GBM), an aggressive and incurable form of brain cancer. In addition, the Company is advancing the development of its WP1244/WP1874 drug technology, which utilizes anthracycline and distamycin-based scaffolds to create small molecule agents. The Company is also evaluating the use of WP1244/WP1874 in the treatment of other primary brain and central nervous system cancers, as well as cancers metastatic to the brain including pancreatic, ovarian, and lymphomas.

Price
Delayed
$2.56
Day's Change
-0.12 (-4.48%)
Bid
--
Ask
--
B/A Size
--
Day's High
2.72
Day's Low
2.48
Volume
(Light)

Today's volume of 83,619 shares is on pace to be much lighter than CNSP's 10-day average volume of 1,263,378 shares.

83,619

Bragar Eagel & Squire, P.C. Is Investigating Veradigm, Techtronics, Marathon, and Nutanix and Encourages Investors to Contact the Firm

9:00 pm ET March 17, 2023 (Globe Newswire) Print
Bragar Eagel & Squire, P.C. Is Investigating Veradigm, Techtronics, Marathon, and Nutanix and Encourages Investors to Contact the FirmGlobeNewswireMarch 18, 2023

NEW YORK, March 17, 2023 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Veradigm Inc. (NASDAQ: MDRX), Techtronic Industries Company Limited (OTC Pink: TTNDY), Marathon Digital Holdings, Inc. (NASDAQ: MARA), and Nutanix, Inc. (NASDAQ: NTNX). Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices. Additional information about each case can be found at the link provided.

Veradigm Inc. (NASDAQ: MDRX)

On February 28, 2023, Veradigm disclosed that it "detected certain internal control failures related to revenue recognition that have occurred over the prior six quarters, resulting in a mis-statement to reported revenues during those periods." As a result, the Company reported that it expects "a reduction in revenue from continuing operations of approximately $20 million dollars in the aggregate from what it otherwise reported since the 3rd quarter of 2021 and expected to report for the 4th quarter of 2022." The Company added that it is "continuing to evaluate the materiality of the mis-statement to determine if the full amount of this adjustment will flow through in the 4th quarter of 2022 or if prior periods will also require adjustment." As a result, Veradigm revised its 2023 guidance downward and announced that it would not be filing its 2022 annual report on time.

On this news, Veradigm's stock price fell $2.12 per share, or 12.76%, to close at $14.49 per share on March 1, 2023.

For more information on the Veradigm investigation go to: https://www.bespc.com/cases/MDRX

Techtronic Industries Company Limited (OTC Pink: TTNDY)

Hong Kong power tool maker Techtronics has gained U.S.-based investors' attention by reporting improved gross profit margin every half-year, sequentially, for ten years straight - a feat no other public company with over $1 billion revenue in the entire world can claim.

Techtronics' earnings recently came into question on Feb. 22, 2023, when Jehoshaphat Research published a report alleging that the company has been "inflating its profits dramatically for over a decade with manipulative accounting."

Specifically, Jehoshaphat Research accuses the company of deceptively managing costs "[b]y stuffing billions of dollars' worth of routine expenses into various asset accounts, year after year;" an accounting trick referred to as "snowballing."

Jehoshaphat Research observes that every year, TTI disposes of large amounts of tangible assets, such as Property, Plant & Equipment, at near-total losses on sale - signifying the company is capitalizing routine business expenses into assets.

The report also accused the company of ignoring its own accounting policy on bad debt provisions to delay expenses.

On this news, Techtronics' share price declined sharply.

For more information on the Techtronics investigation go to: https://www.bespc.com/cases/TTNDY

Marathon Digital Holdings, Inc. (NASDAQ: MARA)

On February 28, 2023, Marathon issued a press release "announc[ing] . . . that it has cancelled its webcast and conference call for the fourth quarter and fiscal year 2022, initially scheduled for today, February 28, 2023, at 4:30 p.m. Eastern time, and will postpone the publication of its corresponding financial results." That same day, Marathon disclosed receipt of a letter from the U.S. Securities and Exchange Commission relating to accounting errors in the Company's previously issued financial statements. The Company advised investors that the "statements contained in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2021 and the previously issued unaudited condensed consolidated financial statements for the interim periods in 2022 and 2021 as contained in the Company's Quarterly Reports on Form 10-Q for the fiscal periods ended March 31, 2021 and 2022, June 30, 2021 and 2022 and September 30, 2021 and 2022 . . . should no longer be relied upon" and will be restated.

On this news, Marathon's stock price fell $0.59 per share, or 8.31%, to close at $6.51 per share on March 1, 2023.

For more information on the Marathon investigation go to: https://www.bespc.com/cases/MARA

Nutanix, Inc. (NASDAQ: NTNX)

On March 6, 2023, Nutanix issued a press release reporting selected preliminary second quarter fiscal 2023 financial results. Among other items, Nutanix reported that "Company management discovered that certain evaluation software from one of its third-party providers was instead used for interoperability testing, validation and customer proofs of concept over a multi-year period." Due to an ongoing Audit Committee investigation into the matter, Nutanix stated that "it does not expect to be able to [timely] file its Quarterly Report on Form 10-Q for the quarter ended January 31, 2023[.]"

On this news, Nutanix's stock price fell $2.27 per share, or 7.89%, to close at $26.50 per share on March 7, 2023.

For more information on the Nutanix investigation go to: https://www.bespc.com/cases/NTNX

About Bragar Eagel & Squire, P.C.:

Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, California, and South Carolina. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact Information:

Bragar Eagel & Squire, P.C.

Brandon Walker, Esq.

Melissa Fortunato, Esq.

(212) 355-4648

investigations@bespc.com

www.bespc.com





Primary Logo

comtex tracking

COMTEX_426898670/2010/2023-03-17T21:00:01

Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2023. All rights reserved.